Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
82.72 EUR | -1.87% | +2.67% | +37.21% |
Apr. 02 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
Mar. 12 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+37.04% | 4.67B | |
+33.25% | 699B | |
+25.13% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+14.83% | 236B | |
+5.34% | 198B | |
-9.61% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2023 Earnings Call, Feb 27, 2024